微电生理(688351) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of 413.17 million yuan, a year-on-year increase of 25.51%[6] - Net profit attributable to shareholders of the parent company reached 52.19 million yuan, up 817.40% compared to the previous year[6] - Basic earnings per share increased to 0.1109 yuan, reflecting a growth of 816.53% year-on-year[8] - The net profit after deducting non-recurring gains and losses turned from a loss to a profit, primarily due to revenue growth and cost reduction efforts[8] Asset and Return Metrics - Total assets at the end of the reporting period were 1,892.23 million yuan, a 3.78% increase from the beginning of the period[6] - The company’s weighted average return on net assets rose to 3.05%, an increase of 2.71 percentage points[2] International Business Growth - The company’s overseas business revenue grew by over 60% year-on-year, contributing to the overall revenue increase[7] - The company has commercialized its products in over 20 countries, accelerating the internationalization of domestic electrophysiology high-end medical devices[7] Product Sales and Market Trends - The sales proportion of high-value consumables such as TrueForce® pressure monitoring RF ablation catheters continued to increase[7] Financial Data Disclaimer - Investors are advised to note that the financial data presented are preliminary and unaudited, with final results to be disclosed in the annual report[9]